85 related articles for article (PubMed ID: 21505085)
21. A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice.
van Waterschoot RA; Schinkel AH
Pharmacol Rev; 2011 Jun; 63(2):390-410. PubMed ID: 21490128
[TBL] [Abstract][Full Text] [Related]
22. Enhanced oral bioavailability of docetaxel in rats by four consecutive days of pre-treatment with curcumin.
Yan YD; Kim DH; Sung JH; Yong CS; Choi HG
Int J Pharm; 2010 Oct; 399(1-2):116-20. PubMed ID: 20727390
[TBL] [Abstract][Full Text] [Related]
23. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093).
Kuppens IE; Bosch TM; van Maanen MJ; Rosing H; Fitzpatrick A; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2005 Jan; 55(1):72-8. PubMed ID: 15316750
[TBL] [Abstract][Full Text] [Related]
24. A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.
Yong WP; Wang LZ; Tham LS; Wong CI; Lee SC; Soo R; Sukri N; Lee HS; Goh BC
Cancer Chemother Pharmacol; 2008 Jul; 62(2):243-51. PubMed ID: 17909805
[TBL] [Abstract][Full Text] [Related]
25. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans.
van Zuylen L; Verweij J; Nooter K; Brouwer E; Stoter G; Sparreboom A
Clin Cancer Res; 2000 Jul; 6(7):2598-603. PubMed ID: 10914699
[TBL] [Abstract][Full Text] [Related]
26. High plasma levels and effective lymphatic uptake of docetaxel in an orally available nanotransporter formulation.
Nassar T; Attili-Qadri S; Harush-Frenkel O; Farber S; Lecht S; Lazarovici P; Benita S
Cancer Res; 2011 Apr; 71(8):3018-28. PubMed ID: 21363913
[TBL] [Abstract][Full Text] [Related]
27. Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure.
Rudek MA; Chang CY; Steadman K; Johnson MD; Desai N; Deeken JF
Cancer Chemother Pharmacol; 2014 Apr; 73(4):729-36. PubMed ID: 24488374
[TBL] [Abstract][Full Text] [Related]
28. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.
Bosch TM; Huitema AD; Doodeman VD; Jansen R; Witteveen E; Smit WM; Jansen RL; van Herpen CM; Soesan M; Beijnen JH; Schellens JH
Clin Cancer Res; 2006 Oct; 12(19):5786-93. PubMed ID: 17020985
[TBL] [Abstract][Full Text] [Related]
29. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans.
Marre F; Sanderink GJ; de Sousa G; Gaillard C; Martinet M; Rahmani R
Cancer Res; 1996 Mar; 56(6):1296-302. PubMed ID: 8640817
[TBL] [Abstract][Full Text] [Related]
30. Effects of paclitaxel, docetaxel and their combinations on subcutaneous lymphomas in inbred Sprague-Dawley/Cub rats.
Otová B; Václavíková R; Danielová V; Holubová J; Ehrlichová M; Horský S; Soucek P; Simek P; Gut I
Eur J Pharm Sci; 2006 Dec; 29(5):442-50. PubMed ID: 17000091
[TBL] [Abstract][Full Text] [Related]
31. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC
Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070
[TBL] [Abstract][Full Text] [Related]
32. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
Yasuda K; Lan LB; Sanglard D; Furuya K; Schuetz JD; Schuetz EG
J Pharmacol Exp Ther; 2002 Oct; 303(1):323-32. PubMed ID: 12235267
[TBL] [Abstract][Full Text] [Related]
33. Development of docetaxel-loaded intravenous formulation, Nanoxel-PM™ using polymer-based delivery system.
Lee SW; Yun MH; Jeong SW; In CH; Kim JY; Seo MH; Pai CM; Kim SO
J Control Release; 2011 Oct; 155(2):262-71. PubMed ID: 21704664
[TBL] [Abstract][Full Text] [Related]
34. NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer.
Hilli J; Sailas L; Jyrkkiö S; Pyrhönen S; Laine K
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1353-62. PubMed ID: 20798939
[TBL] [Abstract][Full Text] [Related]
35. Bioavailability and tissular distribution of docetaxel, a P-glycoprotein substrate, are modified by interferon-alpha in rats.
Ben Reguiga M; Bonhomme-Faivre L; Farinotti R
J Pharm Pharmacol; 2007 Mar; 59(3):401-8. PubMed ID: 17331344
[TBL] [Abstract][Full Text] [Related]
36. Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing dogs.
McEntee MC; Rassnick KM; Lewis LD; Zgola MM; Beaulieu BB; Balkman CE; Page RL
Am J Vet Res; 2006 Jun; 67(6):1057-62. PubMed ID: 16740102
[TBL] [Abstract][Full Text] [Related]
37. Gut instincts: CYP3A4 and intestinal drug metabolism.
Thummel KE
J Clin Invest; 2007 Nov; 117(11):3173-6. PubMed ID: 17975661
[TBL] [Abstract][Full Text] [Related]
38. A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man.
Bradshaw-Pierce EL; Eckhardt SG; Gustafson DL
Clin Cancer Res; 2007 May; 13(9):2768-76. PubMed ID: 17473210
[TBL] [Abstract][Full Text] [Related]
39. Effects of experimental hyperlipidaemia on the pharmacokinetics of docetaxel in rats.
Lee JH; Oh JH; Lee YJ
Xenobiotica; 2011 Sep; 41(9):797-804. PubMed ID: 21561320
[TBL] [Abstract][Full Text] [Related]
40. P-Glycoprotein- and cytochrome P-450-mediated herbal drug interactions.
Kumar YS; Adukondalu D; Sathish D; Vishnu YV; Ramesh G; Latha AB; Reddy PC; Sarangapani M; Rao YM
Drug Metabol Drug Interact; 2010; 25(1-4):3-16. PubMed ID: 21417789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
